By an agreement signed on April 30, 2019, Revenio has acquired the entire share capital of CenterVue.

CenterVue is a global company, based in Italy, that develops, manufactures and sells high-technological diagnostic systems for the early detection and the management of sight-threatening pathologies such as Glaucoma, Diabetic Retinopathy and Macular Degeneration.

The acquisition supports Revenio’s goal of strengthening its position as the global market leader in devices for the diagnostics and monitoring of the eye and glaucoma in particular. The well-known brands of both companies, the strong installed device base, and patent-protected technology are an important aspect of the high-quality, more extensive product offering that will be available for the companies’ customers. With this transaction, the companies will provide their customers with all the modern products needed to diagnose Glaucoma.

CenterVue’s imaging products will also allow Revenio’s product portfolio to be expanded beyond Glaucoma into Diabetic Retinopathy and other Macular Diseases, such as age-related Macular Degeneration.